GEMPHARMATECH CO., LTD. — Investor Relations & Filings
About GEMPHARMATECH CO., LTD.
GemPharmatech Co., Ltd. is a global biotechnology company specializing in the development and distribution of genetically engineered mouse models (GEMMs) for biomedical research. The company maintains one of the world's largest repositories of mouse strains, including knockout (KO), conditional knockout (cKO), and humanized models designed for oncology, immunology, and metabolic disease studies. Through its Knockout All Project, GemPharmatech aims to create KO and cKO strains for all protein-coding genes in the mouse genome. Beyond model production, the company provides comprehensive preclinical services such as efficacy testing, safety assessment, phenotyping, and customized gene editing using CRISPR/Cas9 technology. Serving pharmaceutical enterprises, biotechnology firms, and academic institutions, GemPharmatech supports drug discovery and fundamental life science research with high-throughput production capabilities and specialized germ-free mouse facilities.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 药康生物2024年第一次临时股东大会会议资料 | 2024-09-13 | Chinese | |
| 关于以集中竞价交易方式回购公司股份的进展公告 | 2024-09-02 | Chinese | |
| 关于公司2024年半年度募集资金存放与实际使用情况的专项报告 | 2024-08-28 | Chinese | |
| 关于公司2024年半年度利润分配预案的公告 | 2024-08-28 | Chinese | |
| 关于召开2024年第一次临时股东大会的通知 | 2024-08-28 | Chinese | |
| 药康生物2024年半年度报告 | 2024-08-28 | Chinese |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2024
15 filings
| |||||
| 39535788 | 药康生物2024年第一次临时股东大会会议资料 | 2024-09-13 | Chinese | ||
| 39535772 | 关于以集中竞价交易方式回购公司股份的进展公告 | 2024-09-02 | Chinese | ||
| 39535757 | 关于公司2024年半年度募集资金存放与实际使用情况的专项报告 | 2024-08-28 | Chinese | ||
| 39535737 | 关于公司2024年半年度利润分配预案的公告 | 2024-08-28 | Chinese | ||
| 39535722 | 关于召开2024年第一次临时股东大会的通知 | 2024-08-28 | Chinese | ||
| 39535711 | 药康生物2024年半年度报告 | 2024-08-28 | Chinese | ||
| 39535653 | 第二届董事会第七次会议决议公告 | 2024-08-28 | Chinese | ||
| 39535644 | 第二届监事会第六次会议决议公告 | 2024-08-28 | Chinese | ||
| 39535594 | 2024年度“提质增效重回报”行动方案的半年度评估报告 | 2024-08-28 | Chinese | ||
| 39535584 | 药康生物2024年半年度报告摘要 | 2024-08-28 | Chinese | ||
| 39535578 | 关于以集中竞价交易方式回购公司股份的进展公告 | 2024-07-31 | Chinese | ||
| 39535568 | 关于持股5%以上股东权益变动超过1%的提示性公告 | 2024-07-31 | Chinese | ||
| 39535559 | 2023年年度权益分派实施公告 | 2024-07-31 | Chinese | ||
| 39535548 | 华泰联合证券有限责任公司关于江苏集萃药康生物科技股份有限公司差异化分红事项的核查意见 | 2024-07-31 | Chinese | ||
| 39535541 | 关于公司董事长、实际控制人提议中期分红暨落实公司2024年年度“提质增效重回报”行动方案的公告 | 2024-07-17 | Chinese | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
1NKEMIA
Biotechnology company providing R&D and services for the li…
|
IKM | ES | Professional, scientific and te… |
|
2cureX AB
Develops an IVD test using 3D tumoroids to predict patient …
|
2CUREX | SE | Professional, scientific and te… |
|
Abattis Bioceuticals Corp.
Life sciences company aggregating and investing in cannabis…
|
ATTBF | CA | Professional, scientific and te… |
|
Abera Bioscience AB
Develops mucosal vaccines using a proprietary Outer Membran…
|
ABERA | SE | Professional, scientific and te… |
|
ABION Inc.
Clinical-stage biopharma developing therapeutics for oncolo…
|
203400 | KR | Professional, scientific and te… |
|
ABL Bio Inc.
Develops bispecific antibody therapeutics for oncology and …
|
298380 | KR | Professional, scientific and te… |
|
Abnova (Taiwan) Corporation
Global leader in high-throughput production of antibodies a…
|
4133 | TW | Professional, scientific and te… |
|
Abpro Holdings, Inc.
Clinical-stage biotech developing antibody therapeutics for…
|
ABP | US | Professional, scientific and te… |
|
Absci Corp
A generative AI drug creation company developing biologic m…
|
ABSI | US | Professional, scientific and te… |
|
Achiko AG
A digital services platform for cross-border business compl…
|
ACHI | CH | Professional, scientific and te… |
GEMPHARMATECH CO., LTD. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/58096/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=58096 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=58096 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=58096 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 58096}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for GEMPHARMATECH CO., LTD. (id: 58096)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.